Key Highlights

  • GeneDx shares fell 27.04% over one month to $66.03 as screened on Friday, October 23, 2026.
  • The past week brought a 4.49% decline, with the latest session down 1.66%.
  • Shares fell about 6.5% on Tuesday, September 22, from a $97.83 close.
  • Second-quarter revenue was $114.44 million against a $111.01 million consensus.
  • Trailing twelve-month revenue is $454.43 million, up 25.4%.

GeneDx Stock: Why Did Shares Lose 27.04% in a Month?

GeneDx (NASDAQ:WGS) traded at $66.03 on Friday, October 23, 2026, down 27.04% over one month and 4.49% over one week, with the latest session down 1.66%. A research firm linked the late-September selloff, which it put above 9%, to uncertainty over proposed CMS cuts to exome and genome testing rates. It called the reaction probably too extreme.

Health Services, the group the screen places it in, rose 9.54% in the month, so GeneDx lagged by about 36.6 percentage points (calculated). The stock had closed at $97.83 on September 21, so the decline from that level is about 32.5% (calculated).

CMS Rate Worries: How Did the September Selloff Unfold?

On Tuesday, September 22, shares fell about 6.5% in a session to roughly $91.46, on volume well below average. A further fall of about 6.1% to near $71.60 followed on Tuesday, October 6, from $76.27.

Neither session coincided with a company announcement that explains it. Insider sales on September 16, at an average $97.61, were described as covering tax withholding on vested awards, and so are not a clear driver.

The company has not changed its operating message. It has pointed to better collection rates in late 2026 and 2027, so the share-price drop reflects a reset in how investors weigh payment risk against growth.

Second-Quarter Results: Did the Fundamentals Weaken?

GeneDx provides genomic and diagnostic testing, including exome and genome sequencing for rare disease and pediatric patients. It reported second-quarter results on August 3, with revenue of $114.44 million against a consensus of $111.01 million and adjusted earnings of $0.01 per share against an expected loss of $0.19.

Trailing twelve-month revenue is $454.43 million, up 25.4%, after 2025 revenue of $427.54 million, up 39.97%. The trailing net loss is about $106.36 million, and market value is near $2.00 billion.

The stock had been well above its recent averages before September, which left more room for a pullback once reimbursement worries emerged.

October Announcements: What Did the Company Say After the Drop?

On October 1 the company introduced Easy Order for pediatric genomic testing, and on October 7 it presented newborn screening evidence. It announced 27 accepted abstracts on October 19 and plans on October 20 to expand genome testing with long-read sequencing. A research firm raised its price target to $83 from $74 on October 1, cited as a data point.

What to Watch Next: Can November 3 Earnings and CMS Rates Clear the Air?

Results are estimated for around November 3, 2026, with investors looking for collection rates and cash flow improvement that management expects in late 2026 and 2027. The final CMS payment decision remains the key external variable for exome and genome volumes. Newborn screening and long-read sequencing are the product themes the company is emphasising meanwhile.